Skip to main content

Table 3 Summary of Immunotherapy- related Adverse Events (Patients who received at least one dose of study drug)

From: The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial

Parameter BEXIDEM®
(N = 64)
BCG
(N = 73)
P
No. of patients with AE 29 (45.3%) 62 (84.9%) < 0.001
  16 (25.0%) 39 (53.4%) < 0.001
Grade Moderate    
   Grade Severe 7 (10.9%) 12 (16.4%) 0.4593
   Relationship Probable 7 (10.9%) 31 (42.5%) < 0.001
   Relationship Definite 3 (4.7%) 26 (35.6%) < 0.001
No. of patients who discontinued due to an AE 1 (1.6%) 6 (8.2%) 0.121